<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03572335</url>
  </required_header>
  <id_info>
    <org_study_id>PRO18050046</org_study_id>
    <nct_id>NCT03572335</nct_id>
  </id_info>
  <brief_title>Systems Biology of Diffusion Impairment in Human Immunodeficiency Virus (HIV)</brief_title>
  <acronym>BoDI</acronym>
  <official_title>Systems Biology of Diffusion Impairment in HIV--BoDI</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pittsburgh</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Pittsburgh</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diffusing capacity for carbon monoxide (DLco) abnormalities are common in HIV+ individuals&#xD;
      and associated with significant morbidity and mortality. The complexity and the&#xD;
      individualized differences in causes of these abnormalities have been challenging to unravel&#xD;
      using traditional approaches. In this proposal, the investigators construct a systems'&#xD;
      modeling approach to identify novel molecular and clinical pathways contributing to DLco&#xD;
      impairment in HIV+ individuals and to determine predictive signatures of DLco decline in&#xD;
      order to develop strategies to treat and prevent abnormal lung function in this susceptible&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Mechanisms of impairment of diffusing capacity for carbon monoxide (DLco), which affects over&#xD;
      50 percent of HIV+ individuals, are poorly understood. No therapies exist despite significant&#xD;
      impact on quality of life and mortality. Identifying molecular pathways of DLco impairment in&#xD;
      HIV+ individuals and developing ability to predict HIV+ individuals at risk of DLco&#xD;
      impairment is thus of utmost importance for improving care. In this proposal, the&#xD;
      investigators construct a systems' modeling approach to identify molecular and clinical&#xD;
      pathways contributing to DLco impairment in HIV+ individuals. The investigators collect&#xD;
      multiple parallel molecular datasets integrated with detailed pulmonary function,&#xD;
      radiographic, and echocardiographic measurements to build a comprehensive, systems level&#xD;
      model of DLco abnormalities in HIV and to develop predictive models of susceptibility to DLco&#xD;
      worsening. As our preliminary data suggest that certain micro ribonucleic acid (miRNAs), such&#xD;
      as the hypoxia-induced and metabolically active gene (miR-210), may play an important role in&#xD;
      DLco abnormalities in HIV, the investigators then perform hypothesis-testing experiments to&#xD;
      determine the impact of miRNAs on lung epithelial and endothelial cells. The investigators&#xD;
      will utilize a well phenotyped cohort of over 500 HIV+ individuals with associated&#xD;
      biospecimens to execute the aims.&#xD;
&#xD;
      Participants identified to already have specimens available will be scheduled to have PFT&#xD;
      testing, bronchoscopy including bronchial wash with brushes and blood collection.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 6, 2018</start_date>
  <completion_date type="Anticipated">October 2023</completion_date>
  <primary_completion_date type="Anticipated">October 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Identify key causal molecular pathways of DLco impairment.</measure>
    <time_frame>3 years</time_frame>
    <description>elucidating complex associations and causal relationships between clinical characteristics, the host inflammatory response, cellular metabolism, the microbiome, and miRNAs.</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>HIV Infections</condition>
  <condition>Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>HIV positive with normal PFT's</arm_group_label>
    <description>HIV positive with normal baseline DLco. Subjects with DLco&gt;80% predicted after adjustments for Hgb and Co</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HIV positive with mild DLco impairment</arm_group_label>
    <description>HIV positive with mild DLco impairment DLco &lt;80% predicted after adjustments for Hgb and Co.</description>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>PFT's (pulmonary function testing)</intervention_name>
    <description>The routine lung function endpoints of FVC(forced vital capacity), FEV1, FEV1/FVC, and FEF25-75% will be measured with the flow-volume loop recorder before and after bronchodilator administration. The system is calibrated for body temperature and pressure of saturated gas and volumes, per American Thoracic Society (ATS) standards . DLco will be measured using the automated single-breath procedure of the integrated testing system, which conforms with ATS standards.</description>
    <arm_group_label>HIV positive with mild DLco impairment</arm_group_label>
    <arm_group_label>HIV positive with normal PFT's</arm_group_label>
    <other_name>6MWT (6 minute walk test)</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Whole blood, serum, saliva, oral wash, stool&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        18-80 year old men and women who are HIV positive. All will be pulled from previous&#xD;
        HIV/Lung studies done by the same PI&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men and women age 18 to 80&#xD;
&#xD;
          2. HIV positive and participated in previous HLRC(HIV Lung Research Center) study&#xD;
             (PRO10060177, PRO09050521, PRO14070355, PRO08030011, PRO00606151, PRO13050229,&#xD;
             PRO17060077).&#xD;
&#xD;
          3. Negative pregnancy test (for women of child barring capabilities).&#xD;
&#xD;
          4. Have undergone bronchoscopy with BAL(bronchial lavage) and/or brushing for AECs in&#xD;
             storage.&#xD;
&#xD;
          5. Receiving ART (Anti-Retroviral Therapy)and virally-suppressed for at least 6 months.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnancy or breast-feeding. (urine pregnancy done on all females of child bearing&#xD;
             potential-males and females who are at least 1 year post menopausal or surgically&#xD;
             sterile will not be tested)&#xD;
&#xD;
          2. Contraindication to pulmonary function testing (i.e. abdominal or cataract surgery&#xD;
             within 3 months, recent myocardial infarction, etc.).&#xD;
&#xD;
          3. Increasing respiratory symptoms or febrile (temperature &gt;100.40F [380C]) within 4&#xD;
             weeks of study entry.&#xD;
&#xD;
          4. Acute cardiopulmonary issue in the past 4 months.&#xD;
&#xD;
          5. Uncontrolled hypertension at screening visit (systolic &gt; 180 mm Hg or diastolic &gt; 100&#xD;
             mm Hg) from an average of two or more readings. Subject may return for screening after&#xD;
             blood pressure is controlled.&#xD;
&#xD;
          6. Active cancer requiring systemic chemotherapy or radiation.&#xD;
&#xD;
          7. Active infection of lungs, brain, or abdomen.&#xD;
&#xD;
          8. Intravenous drug use or alcohol use that will impair ability to complete study&#xD;
             investigations in the opinion of the investigator.&#xD;
&#xD;
          9. subjects with an upper or lower respiratory tract infection&#xD;
&#xD;
         10. individuals receiving chronic or acute antibiotics in the prior 4 months.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Alison Morris, MD, MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pittsburgh</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Cathy J Kessinger, RN</last_name>
    <phone>412-624-8330</phone>
    <email>kessingercj@pitt.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Pittsburgh department of medicine division of Pulmonary, Allergy and Critical Care medicine</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cathy J Kessinger, RN</last_name>
      <phone>412-624-8330</phone>
      <email>kessingercj@upmc.edu</email>
    </contact>
    <investigator>
      <last_name>Alison M Morris, MD,MS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>June 13, 2018</study_first_submitted>
  <study_first_submitted_qc>June 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 28, 2018</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pittsburgh</investigator_affiliation>
    <investigator_full_name>Alison Morris</investigator_full_name>
    <investigator_title>Professor of Medicine</investigator_title>
  </responsible_party>
  <keyword>HIV</keyword>
  <keyword>emphysema</keyword>
  <keyword>diffusing capacity</keyword>
  <keyword>chronic obstructive pulmonary disease(COPD)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

